Compare Credo Technology Group Holding Ltd (CRDO) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs DexCom, Inc. — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and DexCom, Inc. for 62 Days on average.
| CRDO | DXCM | |
|---|---|---|
Market Cap | $39.82B | $31.86B |
Volume | 9,451,558 | 3,607,070 |
Sector | Technology | Health |
52-Week High | $302.52 | $92.34 |
52-Week Low | $87.81 | $54.84 |
Typical Hold Time | 22 Days | 62 Days |
Enterprise Value | $39.08B | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $211.86, down 3.7% on the day but maintains strong technical momentum with bullish moving averages and key support at $204. The company demonstrates exceptional growth with 114.7% YoY revenue expansion and 33.83% net margins, though valuation multiples remain elevated at P/E of 74.6. Recent earnings beats and analyst consensus of $267.33 price target suggest continued upside potential despite insider selling activity.
Outlook remains positive driven by AI infrastructure demand and optical technology expansion, with management targeting 85%+ revenue growth. Key risks include premium valuation, customer concentration, and execution challenges as the company scales. The stock offers growth exposure to high-speed connectivity solutions but requires monitoring of margin trends and competitive dynamics.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
